Drugs & Targets CHMP adopts positive opinion for Libtayo as adjuvant treatment for high-risk CSCC October 24, 2025Vol.51 No.39
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
News AnalysisRegulatory News How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough October 17, 2025Vol.51 No.38By Claire Marie Porter and Jacquelyn Cobb
Guest Editorial Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding October 17, 2025Vol.51 No.38By Todd Burus, Caree McAfee and Pamela C. Hull
Cancer Policy Dems push GOP to extend ACA credits as part of a deal to end the government shutdown October 17, 2025Vol.51 No.38By Claire Marie Porter
Cancer Policy Federal judge puts temporary block on new round of CDC and HHS layoffs October 17, 2025Vol.51 No.38By Sara Willa Ernst
Cancer Policy Telehealth visits no longer covered by Medicare October 17, 2025Vol.51 No.38By Jacquelyn Cobb
In Brief Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center October 17, 2025Vol.51 No.38
In Brief Robert Uzzo’s job expands to include the Institute for Cancer Research as Jon Chernoff steps down as director of Fox Chase October 17, 2025Vol.51 No.38
In Brief Alison Loren, Adam Cuker, Mikkael Sekeres named to ASH leadership October 17, 2025Vol.51 No.38
